 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123» |
- |||||||||| VAC18193 / J&J
New P3 trial: A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants (clinicaltrials.gov) - Feb 16, 2022
P3, N=2180, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- Ad26.RSV.preF / J&J
Efficacy and immunogenicity of an Ad26.RSV.preF-based vaccine for the prevention of RSV-mediated lower respiratory tract disease by age and risk level subgroups in adults aged =65 years in a randomised, placebo-controlled, phase IIb study (Hall C) - Jan 31, 2022 - Abstract #ECCMID2022ECCMID_1009;
- Ad26.RSV.preF / J&J
Regimen selection and 1.5-year immunogenicity evaluation of prophylactic Ad26.RSV.preF vaccine combinations: a randomised, double-blind, placebo-controlled, adaptive design phase I/IIa study in adults =60 years of age (Hall C) - Jan 31, 2022 - Abstract #ECCMID2022ECCMID_1008;
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. (Pubmed Central) - Jan 19, 2022
The expanded role of the WHO Global Influenza Surveillance and Response System to address the SARS-CoV-2 pandemic was also discussed. This report summarizes the oral presentations given at this meeting for the benefit of the broader medical and scientific community involved in surveillance, treatment and prevention of respiratory virus diseases.
- |||| VAC18193 / J&J
Trial primary completion date: A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years (clinicaltrials.gov) - Jan 19, 2022
P3, N=750, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
This report summarizes the oral presentations given at this meeting for the benefit of the broader medical and scientific community involved in surveillance, treatment and prevention of respiratory virus diseases. Trial primary completion date: Jun 2022 --> Sep 2022
- ||| VAC18193 / J&J
Trial completion date: A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years (clinicaltrials.gov) - Jan 11, 2022
P3, N=750, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Jun 2022 --> Sep 2022 Trial completion date: Jun 2022 --> Sep 2022
- || Ad26.RSV.preF / J&J
Clinical, Review, Journal: The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. (Pubmed Central) - Nov 29, 2021
In the elderly, a nanoparticle F vaccine candidate and Ad26.RSV.preF were considered as two potential effective vaccines. A promising maternal vaccine candidate is still lacking.
- || VAC18193 / J&J
Trial completion: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Nov 24, 2021
P1/2, N=38, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
A promising maternal vaccine candidate is still lacking. Active, not recruiting --> Completed
- || Ad26.RSV.preF / J&J
Clinical, Journal: Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. (Pubmed Central) - Nov 7, 2021
P2a
Coadministration of Fluarix with Ad26.RSV.preF vaccine had an acceptable safety profile and showed no evidence of interference in immune response. The results are compatible with simultaneous seasonal vaccination with both vaccines.
- |||||||||| VAC18193 / J&J
New P3 trial: A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years (clinicaltrials.gov) - Oct 31, 2021
P3, N=750, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- |||||| VAC18193 / J&J
Enrollment open: A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older (clinicaltrials.gov) - Oct 27, 2021
P3, N=880, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
The results are compatible with simultaneous seasonal vaccination with both vaccines. Not yet recruiting --> Recruiting
- |||||| VAC18193 / J&J
Enrollment open: A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection (clinicaltrials.gov) - Oct 27, 2021
P3, N=1113, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| VAC18193 / J&J
Enrollment open: A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old (clinicaltrials.gov) - Oct 27, 2021
P2b, N=240, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| VAC18193 / J&J
New P2b trial: A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old (clinicaltrials.gov) - Oct 19, 2021
P2b, N=240, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- |||||||||| VAC18193 / J&J
New P3 trial: A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older (clinicaltrials.gov) - Oct 7, 2021
P3, N=880, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- |||||||||| VAC18193 / J&J
New P3 trial: A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection (clinicaltrials.gov) - Oct 6, 2021
P3, N=1113, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- Ad26.RSV.preF / J&J
[VIRTUAL] Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_892;
- |||||| VAC18193 / J&J
Enrollment open: EVERGREEN: A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older (clinicaltrials.gov) - Aug 22, 2021
P3, N=23000, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| VAC18193 / J&J
New P3 trial: EVERGREEN: A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older (clinicaltrials.gov) - Jun 1, 2021
P3, N=23000, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- |||| VAC18193 / J&J
Trial completion: A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults (clinicaltrials.gov) - Apr 19, 2021
P2a, N=459, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Ad26.RSV.preF / J&J
[VIRTUAL] PHASE 1/2A SAFETY AND IMMUNOGENICITY STUDY OF AN RSV VACCINE ADENOVIRUS 26 VECTOR ENCODING PREFUSION F (AD26.RSV.PREF) IN SEROPOSITIVE TODDLERS AGED 12–24 MONTHS (Hall 04) - Apr 7, 2021 - Abstract #ESPID2021ESPID_258;
P1/2
Ad26.RSV.preF was well tolerated, elicited humoral and cellular immune responses. Further studies evaluating the immunogenicity and reactogenicity of Ad26.RSV.preF are ongoing in RSV- seronegative toddlers aged 12–24 months.
- || Ad26.RSV.preF / J&J
Clinical, P1 data, Journal: Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older. (Pubmed Central) - Mar 9, 2021
Further studies evaluating the immunogenicity and reactogenicity of Ad26.RSV.preF are ongoing in RSV- seronegative toddlers aged 12–24 months. Ad26.RSV.preF (LD and HD) had an acceptable safety profile and elicited sustained humoral and cellular immune responses after a single immunization in older adults.
- || VAC18193 / J&J
Trial completion date, Trial primary completion date: CYPRESS: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (clinicaltrials.gov) - Mar 9, 2021
P2b, N=5815, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Ad26.RSV.preF (LD and HD) had an acceptable safety profile and elicited sustained humoral and cellular immune responses after a single immunization in older adults. Trial completion date: Jun 2021 --> May 2024 | Trial primary completion date: Jun 2021 --> Jun 2022
- || VAC18193 / J&J
Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (clinicaltrials.gov) - Feb 21, 2021
P1/2, N=669, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Jun 2021 --> May 2024 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial primary completion date: Apr 2021 --> May 2022
- || VAC18193 / J&J
Trial completion: A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older (clinicaltrials.gov) - Feb 17, 2021
P1, N=36, Completed, Sponsor: Janssen Pharmaceutical K.K.
Trial primary completion date: Apr 2021 --> May 2022 Active, not recruiting --> Completed
- | Ad26.RSV.preF / J&J
Journal: Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. (Pubmed Central) - Feb 14, 2021
In contrast, immunization of neonatal mice with FI-RSV resulted in IgG1 RSV F-binding antibodies associated with a Th2 phenotype, no detectable virus-neutralizing antibodies, and a Th2-biased cellular response. These results are supportive for the clinical development of Ad26.RSV.preF for use in infants.
- || VAC18193 / J&J
Trial primary completion date: A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults (clinicaltrials.gov) - Jan 20, 2021
P2a, N=459, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
These results are supportive for the clinical development of Ad26.RSV.preF for use in infants. Trial primary completion date: Jan 2021 --> Sep 2020
- | VAC18193 / J&J
Trial primary completion date: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Dec 23, 2020
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial primary completion date: Jan 2021 --> Sep 2020 Trial primary completion date: Nov 2020 --> Oct 2021
- || VAC18193 / J&J
Enrollment closed: A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older (clinicaltrials.gov) - Oct 28, 2020
P1, N=36, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Trial primary completion date: Nov 2020 --> Oct 2021 Recruiting --> Active, not recruiting
- | VAC18193 / J&J
Enrollment change: A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults (clinicaltrials.gov) - Sep 1, 2020
P2a, N=354, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting N=128 --> 354
- | VAC18193 / J&J
Trial completion date: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (clinicaltrials.gov) - Aug 30, 2020
P1/2, N=669, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
N=128 --> 354 Trial completion date: May 2021 --> May 2022
- | VAC18193 / J&J
Enrollment closed, Enrollment change: A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults (clinicaltrials.gov) - Aug 7, 2020
P2a, N=128, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: May 2021 --> May 2022 Not yet recruiting --> Active, not recruiting | N=450 --> 128
- | VAC18193 / J&J
New P2a trial: A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults (clinicaltrials.gov) - Jun 30, 2020
P2a, N=450, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- | Ad26.RSV.preF / J&J
Preclinical, Journal: Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. (Pubmed Central) - Jun 23, 2020
In contrast, immunization of neonatal mice with FI-RSV resulted in IgG1 RSV F-binding antibodies associated with a Th2 phenotype, no detectable virus-neutralizing antibodies, and a Th2-biased cellular response. These results are supportive for the clinical development of Ad26.RSV.preF for use in infants.
- || VAC18193 / J&J
Enrollment open: A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older (clinicaltrials.gov) - Jun 15, 2020
P1, N=36, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
These results are supportive for the clinical development of Ad26.RSV.preF for use in infants. Not yet recruiting --> Recruiting
- | VAC18193 / J&J
Enrollment closed: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jun 11, 2020
P1/2, N=38, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | VAC18193 / J&J
Trial completion: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - May 13, 2020
P1/2, N=48, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | VAC18193 / J&J
Trial completion date: CYPRESS: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (clinicaltrials.gov) - May 12, 2020
P2b, N=6674, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed Trial completion date: Oct 2021 --> Jun 2021
- || VAC18193 / J&J
New P1 trial: A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older (clinicaltrials.gov) - Apr 20, 2020
P1, N=36, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- | VAC18193 / J&J
Enrollment closed: CYPRESS: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (clinicaltrials.gov) - Jan 22, 2020
P2b, N=6675, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Oct 2021 --> Jun 2021 Recruiting --> Active, not recruiting
- | VAC18193 / J&J
Trial completion date: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Sep 30, 2019
P1/2, N=48, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting Trial completion date: May 2021 --> Oct 2021
- | VAC18193 / J&J
Enrollment open: CYPRESS: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (clinicaltrials.gov) - Sep 4, 2019
P2b, N=5800, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: May 2021 --> Oct 2021 Not yet recruiting --> Recruiting
- | VAC18193 / J&J
Trial completion: A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults (clinicaltrials.gov) - Aug 29, 2019
P1, N=24, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | VAC18193 / J&J
Enrollment open: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jul 11, 2019
P1/2, N=48, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | VAC18193 / J&J
Enrollment closed, Enrollment change: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (clinicaltrials.gov) - Jul 9, 2019
P1/2, N=914, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=667 --> 914
- | VAC18193 / J&J
Enrollment closed, Trial completion date: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Jul 9, 2019
P1/2, N=48, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting | N=667 --> 914 Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Apr 2020
- | VAC18193 / J&J
New P2b trial: CYPRESS: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older (clinicaltrials.gov) - Jun 11, 2019
P2b, N=5800, Not yet recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
- | VAC18193 / J&J
Enrollment closed: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - May 9, 2019
P1/2, N=48, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Apr 2020 Recruiting --> Active, not recruiting
- | VAC18193 / J&J
Enrollment open: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age (clinicaltrials.gov) - Mar 25, 2019
P1/2, N=48, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | VAC18193 / J&J
Enrollment closed: A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults (clinicaltrials.gov) - Feb 20, 2019
P1, N=24, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting